H.R. 7346 · 117th Congress · House

John W. Walsh Alpha-1 Home Infusion Act of 2022

Active· Referred to the Subcommittee on Health.
Introduced
Mar 31, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

John W. Walsh Alpha-1 Home Infusion Act of 2022

This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.

Action Timeline

5
  1. APR 01, 2022•Committee

    Referred to the Subcommittee on Health.

  2. MAR 31, 2022•IntroReferral

    Introduced in House

  3. MAR 31, 2022•IntroReferral

    Introduced in House

  4. MAR 31, 2022•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. MAR 31, 2022•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committees

3

Health Subcommittee

hsif14

Referred: Apr 1, 2022

Active

Ways and Means Committee

hswm00

Referred: Mar 31, 2022

Active

Energy and Commerce Committee

hsif00

Referred: Mar 31, 2022

Active